Free Trial
NASDAQ:ENTO

Entero Therapeutics (ENTO) Stock Price, News & Analysis

Entero Therapeutics logo
$0.49 -0.06 (-11.26%)
Closing price 04:00 PM Eastern
Extended Trading
$0.46 -0.03 (-5.13%)
As of 06:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Entero Therapeutics Stock (NASDAQ:ENTO)

Key Stats

Today's Range
$0.45
$0.49
50-Day Range
$0.35
$0.59
52-Week Range
$0.19
$1.24
Volume
682,609 shs
Average Volume
824,403 shs
Market Capitalization
$2.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ENTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Entero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ENTO Stock News Headlines

Entero Therapeutics Inc ENTO
$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
Entero Therapeutics Delays 10-K Filing
Entero Therapeutics names Richard Paolone as interim CEO
See More Headlines

ENTO Stock Analysis - Frequently Asked Questions

Entero Therapeutics' stock was trading at $0.6220 at the beginning of 2025. Since then, ENTO shares have decreased by 21.7% and is now trading at $0.4870.

Entero Therapeutics, Inc. (NASDAQ:ENTO) released its quarterly earnings data on Thursday, May, 15th. The company reported ($0.21) EPS for the quarter.

Shares of ENTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Entero Therapeutics investors own include Conduit Pharmaceuticals (CDT), BIOLASE (BIOL), Cyclacel Pharmaceuticals (CYCC), Dare Bioscience (DARE), PMGC (ELAB), TRACON Pharmaceuticals (TCON) and Tempest Therapeutics (TPST).

Company Calendar

Last Earnings
5/15/2025
Today
7/10/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ENTO
Previous Symbol
NASDAQ:ENTO
CIK
1604191
Fax
N/A
Employees
9
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$18.06 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($0.82) per share
Price / Book
-0.67

Miscellaneous

Free Float
4,730,000
Market Cap
$2.62 million
Optionable
N/A
Beta
0.84
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:ENTO) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners